20cm速递丨科创创新药ETF（589720）盘中涨超1.8%，去年“924行情”以来跑赢主要港股创新药指数，机构：创新驱动医药板块成长

Core Viewpoint - The pharmaceutical industry in China is transitioning from "Made in China" to "Created in China," with innovative drugs entering a commercialization phase and showing strong performance in the industry chain, indicating a favorable investment opportunity in the coming quarters [1] Group 1: Industry Performance - The performance of innovative drugs and their industry chain is expected to be outstanding as domestic innovative products enter the commercialization cycle and the potential for overseas expansion is released [1] - The industry growth is considered relatively certain in the upcoming quarters, especially with the current low valuation levels providing an excellent entry point for investment in the pharmaceutical sector [1] Group 2: Investment Products - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking an index of 30 representative high-quality companies, primarily in high-growth biotech [1] - The product's 20% price fluctuation limit aligns it more closely with the volatility of the sector, enhancing its appeal to investors [1] Group 3: Market Performance Comparison - Since the "924 market" rally last year, the Sci-Tech Innovation Drug Index has outperformed major Hong Kong innovative drug indices [1] - During the market rebound period from September 24, 2024, to June 30, 2025, the respective gains for the Sci-Tech Innovation Drug Index, Hong Kong Innovative Drug Index, and Hang Seng Hong Kong Stock Connect Innovative Drug Index were 75%, 70%, and 70% [1]